Immunovant Inc (IMVT)

Sep 26, 2026

Christopher Van Tuyl, Immunovant's Chief Legal Officer, sold 2,846 shares of company common stock on September 23, 2026. This mandatory sale, at a weighted average price of $36.36 per share, was conducted to cover tax withholding obligations arising from the vesting of 6,872 restricted stock units (RSUs) on September 16, 2026. This transaction was non-discretionary and part of the issuer's "sell to cover" policy, leaving Van Tuyl with 176,545 directly owned shares.

Sep 24, 2026

Immunovant (IMVT) shares dropped after its lead drug candidate, IMVT-1402, failed to meet the primary endpoint in a study for cutaneous lupus erythematosus (CLE), leading the company to halt development for this indication. Despite positive trends in some measures, the results did not meet internal thresholds given the competitive landscape. Immunovant will continue to develop IMVT-1402 for other autoimmune diseases and expects its current cash reserves to fund operations through a potential launch in Graves' disease.

Sep 24, 2026

Immunovant Inc. (IMVT) announced it is discontinuing the development of IMVT-1402 for cutaneous lupus erythematosus (CLE) after the drug failed to meet its primary endpoint in a proof-of-concept trial. Despite positive safety trends, the company decided to shift focus to other autoimmune conditions due to insufficient clinical outcomes and the competitive landscape. This announcement led to a decline in stock prices for both Immunovant and its parent company, Roivant Sciences Ltd. (ROIV).

Sep 23, 2026

Immunovant (NASDAQ: IMVT) is halting its cutaneous lupus development program after its Phase 2b trial for IMVT-1402, or imeroprubart, failed to meet its primary endpoint at Week 12. The study did not show a statistically significant difference in the CLASI-A score, though numerical trends favored treatment. Despite this setback, Immunovant will continue development for five other autoimmune indications, including Graves' disease and myasthenia gravis, with topline results expected in 2027.

Sep 18, 2026

Immunovant (NASDAQ: IMVT) discussed its Q1 2027 financial results, reporting a quiet quarter but anticipating a busy second half with several key developments. These include the potential launch of brepocitinib for dermatomyositis, the initiation of a phase 3 study for brepocitinib in cutaneous sarcoidosis, and ongoing litigation. The company maintains a strong financial position with nearly $4 billion in cash and accelerated share repurchases, while strategically focusing on a slow and steady commercial approach for brepocitinib to build a foundation for future expansions.

Sep 14, 2026

Immunovant's stock appears expensive based on its price-to-book (P/B) ratio, trading at 10.6x compared to the biotech industry average of 2.3x. Despite strong long-term returns and promising drug programs like imeroprubart for rheumatoid arthritis, analysts are questioning if the current valuation aligns with its book value. The article highlights both bull and bear case narratives, suggesting the stock could be undervalued by 22% or overvalued by 71% depending on future growth and competition.